Summary
Cardinal Health, Inc. (CAH) announced on November 29, 2006, its strategic decision to divest its Pharmaceutical Technologies and Services segment. This move is intended to sharpen the company's focus on its core strengths in serving healthcare providers and expanding its supply chain and medical products businesses. The divestiture is expected to be completed by the first quarter of fiscal year 2008, with the financial results of the disposed segment (excluding the retained Martindale and Beckloff Associates businesses) to be reported as discontinued operations. While the company is actively seeking a buyer and no definitive agreement has been reached, this divestiture signals a significant strategic shift for Cardinal Health. Investors should monitor the progress of this sale, as it aims to streamline operations and reallocate resources towards areas management believes will drive future growth and enhance shareholder value. The company has not yet been able to provide an estimate of the costs or charges associated with this exit activity.
Key Highlights
- 1Cardinal Health is divesting its Pharmaceutical Technologies and Services segment to focus on core businesses.
- 2The sale is expected to be completed by the first quarter of fiscal year 2008.
- 3Financial results of the divested segment will be classified as discontinued operations.
- 4The Martindale and Beckloff Associates businesses will be retained and integrated into the Healthcare Supply Chain Services – Pharmaceutical segment.
- 5The company is unable to estimate the costs and charges associated with the sale at this time.
- 6The announcement was made via a press release filed with the SEC on November 30, 2006.
- 7Additional information regarding financial targets and goals was also publicly disclosed.